ASLAN Keeps Eye On Maximizing Values After Fundraising
This article was originally published in PharmAsia News
ASLAN has closed a Series C round involving some new investors that puts the Singapore venture in a more comfortable financial position and may allow it to complete pivotal trials for its lead oncology project. But its CEO says the main focus will continue to be on maximizing asset values.
You may also be interested in...
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.